Benefit, Risk and Cost in Oral Anticoagulation for Stroke Prevention: Is It the Third Factor?
作者信息
Choi Jong Il
机构信息
Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine and Korea University Medical Center, Seoul, Korea.
出版信息
Korean Circ J. 2019 Mar;49(3):264-266. doi: 10.4070/kcj.2019.0007.
Abstract
摘要
相似文献
1
Benefit, Risk and Cost in Oral Anticoagulation for Stroke Prevention: Is It the Third Factor?口服抗凝剂预防卒中的获益、风险与成本：是第三个因素吗？
Korean Circ J. 2019 Mar;49(3):264-266. doi: 10.4070/kcj.2019.0007.
2
Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation.经皮左心耳封堵术用于房颤且有抗凝禁忌证患者的卒中预防
Rev Neurol (Paris). 2015 May;171(5):426-32. doi: 10.1016/j.neurol.2014.11.009. Epub 2015 Apr 23.
3
Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.新型口服抗凝药用于房颤患者卒中预防的成本效益：取决于华法林抗凝控制的质量
Pharmacoeconomics. 2015 Apr;33(4):395-408. doi: 10.1007/s40273-014-0246-7.
4
The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.美国针对心房颤动且有高卒中风险患者的抗凝管理服务的成本效益
Pharmacoeconomics. 2006;24(10):1021-33. doi: 10.2165/00019053-200624100-00009.
5
Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation.发表的卒中发生率变化对房颤抗凝净临床获益的影响。
Ann Intern Med. 2018 Oct 16;169(8):517-527. doi: 10.7326/M17-2762. Epub 2018 Sep 25.
6
Prevention of stroke in patients with atrial fibrillation.心房颤动患者的卒中预防
Semin Vasc Med. 2005 Aug;5(3):285-92. doi: 10.1055/s-2005-916168.
7
Oral anticoagulation versus antiplatelet or placebo for stroke prevention in patients with heart failure and sinus rhythm: Systematic review and meta-analysis of randomized controlled trials.口服抗凝剂与抗血小板或安慰剂治疗心力衰竭伴窦性心律患者的卒中预防：随机对照试验的系统评价和荟萃分析。
Int J Stroke. 2019 Dec;14(9):856-861. doi: 10.1177/1747493019877296. Epub 2019 Sep 16.
8
Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis.决定对高龄房颤患者进行抗凝治疗：成本效益分析的见解
J Am Geriatr Soc. 2002 May;50(5):863-9. doi: 10.1046/j.1532-5415.2002.50212.x.
9
Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives.心力衰竭合并心房颤动患者抗凝治疗依从性的障碍与促进因素：患者及医疗服务提供者的观点
J Clin Nurs. 2017 Dec;26(23-24):4325-4334. doi: 10.1111/jocn.13759. Epub 2017 Mar 31.
10
Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?心房颤动患者预防卒中的抗凝治疗的成本效益是否被低估了？
Stroke. 2005 Feb;36(2):360-6. doi: 10.1161/01.STR.0000153002.56324.8c. Epub 2005 Jan 6.
本文引用的文献
1
Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation.利伐沙班与华法林相比用于心房颤动卒中预防的成本效益
Korean Circ J. 2019 Mar;49(3):252-263. doi: 10.4070/kcj.2018.0220. Epub 2018 Nov 14.
2
Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges.老年房颤合并症患者预防卒中的抗凝治疗：当前证据与治疗挑战
Korean Circ J. 2018 Oct;48(10):873-889. doi: 10.4070/kcj.2018.0261.
3
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.2018 年欧洲心脏病学会关于非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中应用的实用指南。
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
4
Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.基于远程监测的反馈可改善房颤患者对抗凝药物（非维生素 K 拮抗剂）的依从性。
Eur Heart J. 2018 Apr 21;39(16):1394-1403. doi: 10.1093/eurheartj/ehx762.
5
Cost-Effectiveness Analysis 2.0.成本效益分析2.0
N Engl J Med. 2017 Jan 19;376(3):203-205. doi: 10.1056/NEJMp1612619.
6
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.非瓣膜性心房颤动患者缺血性脑卒中预防的口服抗凝剂成本效益分析。
Stroke. 2016 Jun;47(6):1555-61. doi: 10.1161/STROKEAHA.115.012325. Epub 2016 Apr 21.
7
Essential medicines and health products information portal.基本药物和保健产品信息门户。
J Pharmacol Pharmacother. 2014 Jan;5(1):74-5. doi: 10.4103/0976-500X.124434.
8
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较：随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
9
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.阿哌沙班、达比加群、利伐沙班和华法林预防房颤卒中的成本效益分析。
Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.
10
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.利伐沙班与华法林预防房颤卒中的成本效果比较。
Am J Cardiol. 2012 Sep 15;110(6):845-51. doi: 10.1016/j.amjcard.2012.05.011. Epub 2012 May 30.
Zotero 插件